Menu
← Oncology Approval Tracker
FDA DECISION ·
Oxderys
doxorubicin hydrochloride injection · AVYXA Holdings
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Doxorubicin injection for multi-agent adjuvant treatment of node-positive breast cancer after resection, and the leukemias, lymphomas and metastatic solid tumors specified in its FDA labeling. The full label defines each authorized use.
SUPPORTING DATA
Evidence behind the decision
- Study
- NDA 221093: original product approval under section 505(b)(2).
- Key result
- FDA authorized the product for the uses in its agreed labeling; no comparative superiority is established by the approval letter.
- Safety to report
- Boxed warnings cover cardiomyopathy, secondary malignancies, extravasation/tissue necrosis and severe myelosuppression.
- Evidence limits
- Approval does not establish commercial availability, a new mechanism or an efficacy advantage over other doxorubicin products.
LAMPGEN ANALYSIS
Why it matters
An original 505(b)(2) product NDA for an established active ingredient. This action is neither a new molecular entity nor a first-generic approval.
What research teams should watch
Check the exact vial presentation, pharmacy preparation, cumulative anthracycline exposure and extravasation procedures against the study protocol and approved label.
PRIMARY RECORDS